tert-butyl 2-chlorophenyl sulfide | 84051-21-8

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: tert-butyl 2-chlorophenyl sulfide
• 英文别名: 1-(tert-Butylsulfanyl)-2-chlorobenzene；1-tert-butylsulfanyl-2-chlorobenzene
• CAS: 84051-21-8
• 化学式: C₁₀H₁₃ClS
• 分子量: 200.732
• InChiKey: DUMIIJLRONWCIL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  25.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  叔丁基硫醇 、 邻二氯苯 生成 tert-butyl 2-chlorophenyl sulfide
  参考文献：
  名称：

  Nucleophilic aromatic substitution of Cr(CO)3 complexed dihaloarenes with thiolates

  摘要：

  DOI：

  10.1021/jo00166a040

文献信息

• 1-(TRIAZIN-3-YL/PYRIDAZIN-3-YL)-PIPER(-AZINE)IDINE DERIVATIVES AND COMPOSITIONS THEREFOR FOR INHIBITING THE ACTIVITY OF SHP2
  申请人：CHEN Zhuoliang

  公开号：US20170001975A1

  公开（公告）日：2017-01-05

  The present invention relates to compounds of formula I: in which Y 1 , Y 2 , Y 3 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

  本发明涉及以下式I的化合物： 其中Y1、Y2、Y3、R1、R2a、R2b、R3a、R3b、R4a、R4b、R5a、R5b在发明摘要中有定义；能够抑制SHP2活性。本发明还提供了一种制备该类化合物的方法，包括含有这类化合物的药物制剂以及在管理与SHP2异常活性相关的疾病或疾病的方法中使用这类化合物和组合物。
• N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2
  申请人：Chen Christine Hiu-Tung

  公开号：US20170015680A1

  公开（公告）日：2017-01-19

  The present invention relates to compounds of formula I: in which p, q, Y 1 , Y 2 , R 1 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 7 and R 8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

  本发明涉及以下式I的化合物： 其中p、q、Y1、Y2、R1、R2a、R2b、R3a、R3b、R4a、R4b、R5a、R5b、R7和R8在本发明概要中有定义；能够抑制SHP2活性。本发明还提供了一种制备本发明化合物的方法，包括含有这些化合物的药物制剂以及在管理与SHP2异常活性相关的疾病或疾病的方法中使用这些化合物和组合物。
• TRIAZINE DERIVATIVES AND THEIR THERAPEUTICAL APPLICATIONS
  申请人：Tao Chunlin

  公开号：US20120172361A1

  公开（公告）日：2012-07-05

  Compounds of the formula (I) and formula (II) and pharmaceutically acceptable salts thereof.

  公式（I）和公式（II）的化合物及其药学上可接受的盐。
• Process for the nucleophilic substitution of unactivated aromatic and heteroaromatic substrates
  申请人：E.I. DU PONT DE NEMOURS AND COMPANY

  公开号：EP0094821A1

  公开（公告）日：1983-11-23

  A process for achieving nucleophilic substitution upon an unactivated monocyclic or polycyclic aromatic or heteroaromatic substrate bearing a suitable leaving group comprising the substitution of said leaving group by an anionic nucleophile is catalyzed with a cyclic or acyclic polydentate chelating ligand, e.g. a crown ether or a cyclic polyether. The process is applicable, inter alia, as the first step in the preparation of ortho-substituted benzenesulfonyl chloride derivatives, or ortho-benzenedithiol, from ortho-dichlorobenzene.

  一种在带有适当离去基团的未活化单环或多环芳香族或杂芳族底物上实现亲核取代的工艺，包括在环状或无环多齿螯合配体（例如冠醚或环状聚醚）的催化下用阴离子亲核剂取代所述离去基团。该工艺尤其适用于从邻二氯苯制备邻取代苯磺酰氯衍生物或邻苯二硫醇的第一步。
• N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2
  申请人：NOVARTIS AG

  公开号：US10968235B2

  公开（公告）日：2021-04-06

  The present invention relates to compounds of formula I: in which p, q, Y1, Y2, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a, R5b, R7 and R8 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

  本发明涉及式 I 的化合物： 其中p、q、Y1、Y2、R1、R2a、R2b、R3a、R3b、R4a、R4b、R5a、R5b、R7和R8在发明概述中定义；能够抑制SHP2的活性。本发明进一步提供了制备本发明化合物的工艺、包含此类化合物的药物制剂以及使用此类化合物和组合物治疗与SHP2活性异常有关的疾病或失调的方法。